I den farmakokinetiske analyse med poolet population sås ingen klar forskel i rosiglitazons farmakokinetik hos kvinder og mænd.
In the pooled population pharmacokinetic analysis, there were no marked differences in the pharmacokinetics of rosiglitazone between males and females.